These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3321546)

  • 1. Stimulation of the plasma fibrinolytic activity in rats by the prostacyclin analogue CG 4203.
    Schneider J
    Thromb Res; 1987 Oct; 48(2):233-44. PubMed ID: 3321546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salutary effects of the prostacyclin analogue CG 4203 in lethal endotoxemia in rats.
    Schneider J
    Prostaglandins Leukot Essent Fatty Acids; 1988 Mar; 31(3):139-46. PubMed ID: 3287395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibrinolytic activity of prostacyclin and iloprost in patients with peripheral arterial disease.
    Musiał J; Wilczyńska M; Sładek K; Cierniewski CS; Nizankowski R; Szczeklik A
    Prostaglandins; 1986 Jan; 31(1):61-70. PubMed ID: 2419945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerance and pharmacology of ciprostene, a stable epoprostenol (prostacyclin) analogue in humans.
    Linet OI; Nishizawa EE; Schaub RG; VanderLugt JT; Greenwald CA
    J Clin Pharmacol; 1986 Feb; 26(2):131-40. PubMed ID: 3005377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrinolytic action of a new semi-synthetic polysaccharide sulfate, galactan polysulfate (DH 6322), in the rat.
    Kumada T; Abiko Y
    Thromb Res; 1985 Jul; 39(1):9-19. PubMed ID: 4035651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between gender difference in intravascular aggregation of platelets and the fibrinolytic pathway in the rat.
    Oyekan AO; Botting JH
    Arch Int Pharmacodyn Ther; 1991; 313():176-92. PubMed ID: 1816761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium nitroprusside modulates the fibrinolytic system in the rabbit.
    Lidbury PS; Korbut R; Vane JR
    Br J Pharmacol; 1990 Nov; 101(3):527-30. PubMed ID: 2127549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity.
    Echart CL; Graziadio B; Somaini S; Ferro LI; Richardson PG; Fareed J; Iacobelli M
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):627-34. PubMed ID: 19809307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro analysis of synergistic effects of fibrinolytic agents and prostacyclin analogues.
    Spiecker M; Heinke B; Meyer J; Darius H
    Haemostasis; 1997; 27(4):184-92. PubMed ID: 9483173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of recombinant plasminogen activator inhibitor type 1 on fibrinolysis in vitro and in vivo.
    Knabb RM; Chiu AT; Reilly TM
    Thromb Res; 1990 Jul; 59(2):309-17. PubMed ID: 2122539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activator inhibitor-1 suppresses endogenous fibrinolysis in a canine model of pulmonary embolism.
    Reilly CF; Fujita T; Hutzelmann JE; Mayer EJ; Shebuski RJ
    Circulation; 1991 Jul; 84(1):287-92. PubMed ID: 1905594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
    Gurewich V; Pannell R
    Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.
    Electricwala A; Ling RJ; Sutton PM; Griffiths B; Riley PA; Atkinson T
    Thromb Haemost; 1985 Apr; 53(2):200-3. PubMed ID: 4040659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotic properties of water-soluble carbon monoxide-releasing molecules.
    Kramkowski K; Leszczynska A; Mogielnicki A; Chlopicki S; Fedorowicz A; Grochal E; Mann B; Brzoska T; Urano T; Motterlini R; Buczko W
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2149-57. PubMed ID: 22772756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.
    Collen D; Stassen JM; Verstraete M
    J Clin Invest; 1983 Feb; 71(2):368-76. PubMed ID: 6681615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Plasminogen activator from a kidney cell culture].
    Andreenko GV; Egorov BB; Liaginskiĭ AV; Serebriakova TN; Podorol'skaia LV
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1983; (10):55-8. PubMed ID: 6686063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
    Gurewich V; Pannell R
    Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The inhibitory effect of aspirin on fibrinolysis is reversed by iloprost, a prostacyclin analogue.
    Bertelé V; Mussoni L; Pintucci G; del Rosso G; Romano G; de Gaetano G; Libretti A
    Thromb Haemost; 1989 Apr; 61(2):286-8. PubMed ID: 2473539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrin-specific fibrinolysis induced by recombinant staphylokinase.
    Shishido Y; Matsumoto T; Sakai M; Kaneda N; Sansawa H; Shimura K; Hashimoto S; Yokokura T
    Biol Pharm Bull; 1994 Aug; 17(8):1060-4. PubMed ID: 7820108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.